D

Dynavax Technologies Corp
D

DVAX

12.420
USD
0.06
(0.44%)
Market Closed
Volume
43,361
EPS
0
Div Yield
-
P/E
83
Market Cap
1,632,665,648
OverviewSignalsIdeasNews
Related Instruments
    A
    ALT
    -0.85500
    (-10.11%)
    7.60000 USD
    B
    BCRX
    -0.41500
    (-5.57%)
    7.03500 USD
    E
    EBS
    -1.55000
    (-16.74%)
    7.71000 USD
    GSK
    GSK
    -1.020
    (-2.97%)
    33.350 USD
    I
    INO
    -0.54000
    (-11.25%)
    4.26000 USD
    MRNA
    MRNA
    -2.950
    (-7.42%)
    36.830 USD
    N
    NVAX
    0.12000
    (1.67%)
    7.32500 USD
    S
    SVA
    0
    (0%)
    0.000000 USD
    TAK
    TAK
    0.060
    (0.44%)
    13.625 USD
    V
    VSTM
    -0.13500
    (-3.26%)
    4.00000 USD
    More
News

Title: Dynavax Technologies Corp

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.